Inter-partes review has become an increasingly popular way to challenge patents, accounting for 92% of all post-grant trials. Inter-partes review was implemented in 2011 as part of the America Invents Act as an alternative to challenge validity of patents outside of litigation. Since implementation, bio & pharma patents have been increasingly subjected to these petitions. Discussed in this presentation will be an overview of different strategies behind challenging patents in this way. We will examine the legal implications and considerations when implementing these challenges utilizing recent case studies. In addition, we will discuss strategies for patent holders.<br/>

Post-grant review proceedings of chemical & pharma patents: Brief overview and analysis of noteworthy proceedings

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.